Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126288) titled 'Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency' on Aug. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.
Condition:
Growth Hormone Deficiency in Children
Growth Hormone Deficiency (GHD)
Growth Hormone
Intervention:
Drug: GB08
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: August 31, 2025
Target Sample Size: 268
Countries of R...